References

References

  1. Fairlamb AH et al. Nat Microbiol 2016;1(7): e16092.
  2. Agrawal S et al. J Antimicrob Chemother 2016;71 Suppl 2: ii37-ii42.
  3. Schmiedel Y et al. Swiss Med Wkly 2016;146: w14281.
  4. Global Action Fund for Fungal Infections (GAFFI). Hidden Crisis. June 2016. Website: https://www.gaffi.org/wp-content/uploads/GAFFI-Leaflet-June-2016-DWD-hidden-crisis.pdf (Accessed April 2018).
  5. O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. The review on antimicrobial resistance; London: HM Government and the Wellcome Trust; 2016.
  6. Bongomin F et al. J. Fungi 2017;3(4): 57.
  7. Rüping MJ et al. Drugs 2008;68(14): 1941-62.
  8. The Guardian newspaper. Millions at risk as deadly fungal infections acquire drug resistance. August 2016. Web: https://www.theguardian.com/society/2016/aug/27/millions-at-risk-as-deadly-fungal-infections-acquire-drug-resistance (Accessed April 2018).
  9. Pegorie M et al. J. Infect. Jan 2017;74(1): 60–71.
  10. Fungal Diseases in the UK. Health Protection Agency. April 2006. Web: http://webarchive.nationalarchives.gov.uk/20140714110452/http:/www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1196942156347 (Accessed April 2018)
  11. Valerio M et al. J Antimicrob Chemother 2014;69: 1993-9.
  12. Arendrup MC et al. Clin Microbial Infect 2014;20 (Suppl. 6): 42-48.
  13. Bougnoux ME et al. Intensive Care Med 2008;34(2): 292-9.
  14. Barnes R et al. Clin Thera 2015;37(6): 1317-1328.e2.
  15. Roberts RR et al. Clin Infect Dis 2009;49(8): 1175-84.
  16. Ceesay MM et al. J Antimicrob Chemother 2015;70: 1175-1181.